Market Closed -
Nasdaq
04:00:00 2024-05-15 pm EDT
5-day change
1st Jan Change
42.44
USD
+2.76%
+0.54%
-31.38%
Presentation Operator MessageOperator (Operator)Greetings, and welcome to the Amphastar Pharma...
This article is reserved for subscribers
Signed up already?
Log In Not subscribed yet?
Subscribe
Transcript : Amphastar Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 08, 2024
May. 08
Amphastar Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
May. 08
CI
Earnings Flash (AMPH) AMPHASTAR PHARMACEUTICALS Reports Q1 EPS $1.04, vs. Street Est of $0.79
May. 08
MT
Earnings Flash (AMPH) AMPHASTAR PHARMACEUTICALS Reports Q1 Revenue $171.8M, vs. Street Est of $174.7M
May. 08
MT
FTC Challenging 'Junk' Patent Listings for Ozempic, Victoza, Other Medications
Apr. 30
MT
Top Midday Stories: Shares of Eli Lilly, HSBC Get Post-Earnings Bump; BBVA Exploring Merger With Sabadell; FTC Disputes 300 'Junk' Patent Listings
Apr. 30
MT
FTC Challenging 'Junk' Patent Listings for Ozempic, Victoza, Other Medications
Apr. 30
MT
FTC Challenging 'Junk' Patent Listings for Ozempic, Victoza, Other Medications
Apr. 30
MT
FTC Challenging 'Junk' Patent Listings for Ozempic, Victoza, Other Medications
Apr. 30
MT
Transcript : Amphastar Pharmaceuticals, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 11:15 AM
Mar. 13
Amphastar Pharmaceuticals Insider Sold Shares Worth $842,883, According to a Recent SEC Filing
Mar. 08
MT
JPMorgan Initiates Amphastar Pharmaceuticals With Overweight Rating, Price Target is $60
Mar. 05
MT
Sector Update: Health Care Stocks Advance Premarket Thursday
Feb. 29
MT
Amphastar Pharmaceuticals Q4 Adjusted Earnings, Revenue Rise
Feb. 29
MT
Transcript : Amphastar Pharmaceuticals, Inc., Q4 2023 Earnings Call, Feb 28, 2024
Feb. 28
Amphastar Pharmaceuticals, Inc. Reports Impairment of Long-Lived Assets for the Fourth Quarter Ended December 31, 2023
Feb. 28
CI
Amphastar Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023
Feb. 28
CI
Earnings Flash (AMPH) AMPHASTAR PHARMACEUTICALS Posts Q4 EPS $0.88, vs. Street Est of $0.91
Feb. 28
MT
Earnings Flash (AMPH) AMPHASTAR PHARMACEUTICALS Reports Q4 Revenue $178.1M, vs. Street Est of $173.3M
Feb. 28
MT
High-dose opioid reversal spray no better than lower dose in field, US study finds
Feb. 08
RE
Amphastar Pharmaceuticals Insider Sold Shares Worth $7,171,768, According to a Recent SEC Filing
Jan. 11
MT
Amphastar Pharmaceuticals Insider Sold Shares Worth $12,798,708, According to a Recent SEC Filing
Jan. 11
MT
Transcript : Amphastar Pharmaceuticals, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-10-2024 09:00 AM
Jan. 10
MannKind Restructures Supply Agreement with Amphastar Pharmaceuticals
Dec. 28
MT
Amphastar Pharmaceuticals Insider Sold Shares Worth $223,446, According to a Recent SEC Filing
Nov. 21
MT
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Amphastar Pharmaceuticals, Inc. is a biopharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically challenging generic and injectable, inhalation, and intranasal products. Additionally, it sells insulin API products. Most of its finished products are used in hospital or urgent care clinical settings and are primarily contracted and distributed through group purchasing organizations and drug wholesalers. Its segments include finished pharmaceutical products and API products. The finished pharmaceutical products segment manufactures, markets and distributes Primatene MIST, epinephrine, glucagon, phytonadione, lidocaine, enoxaparin, naloxone, as well as various other critical and non-critical care drugs. The API segment manufactures and distributes RHI API and porcine insulin API for external customers and internal product development. Its pipeline has over 20 product candidates, including generic ANDAs, biosimilar, and others.
More about the company
Last Close Price
41.3
USD
Average target price
62.6
USD
Spread / Average Target
+51.57%
Consensus
1st Jan change
Capi.
-31.38% 2.02B +31.37% 588B -2.60% 364B +20.83% 326B +5.69% 285B +14.83% 239B +9.93% 210B -6.95% 200B +10.77% 167B +0.10% 161B
Other Pharmaceuticals
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1